OCGN Valuation

Ocugen Inc

Add to Watchlist

Advanced Chart

0.958

+0.003(0.314%)1D

Overview
Forecast
Valuation
Earnings

OCGN Relative Valuation

OCGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, OCGN is overvalued; if below, it's undervalued.

Historical Valuation

Ocugen Inc (OCGN) is now in the Fair zone, suggesting that its current forward PS ratio of 395.69 is considered Fairly compared with the five-year average of -27.09. The fair price of Ocugen Inc (OCGN) is between 0.29 to 1.49 according to relative valuation methord.

Relative Value

Fair Zone

0.29-1.49

Current Price：0.95

Fair

-4.34

Trailing

Forward

0.00

EV/EBITDA

Ocugen Inc. (OCGN) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-4.69

EV/EBIT

Ocugen Inc. (OCGN) has a current EV/EBIT of -4.69. The 5-year average EV/EBIT is -6.13. The thresholds are as follows: Strongly Undervalued below -56.74, Undervalued between -56.74 and -31.43, Fairly Valued between 19.18 and -31.43, Overvalued between 19.18 and 44.49, and Strongly Overvalued above 44.49. The current Forward EV/EBIT of -4.69 falls within the Historic Trend Line -Fairly Valued range.

398.24

Ocugen Inc. (OCGN) has a current PS of 398.24. The 5-year average PS is 139.81. The thresholds are as follows: Strongly Undervalued below -330.24, Undervalued between -330.24 and -95.22, Fairly Valued between 374.83 and -95.22, Overvalued between 374.83 and 609.85, and Strongly Overvalued above 609.85. The current Forward PS of 398.24 falls within the Overvalued range.

0.00

P/OCF

Ocugen Inc. (OCGN) has a current P/OCF of 0.00. The 5-year average P/OCF is -11.09. The thresholds are as follows: Strongly Undervalued below -134.66, Undervalued between -134.66 and -72.88, Fairly Valued between 50.69 and -72.88, Overvalued between 50.69 and 112.47, and Strongly Overvalued above 112.47. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Ocugen Inc. (OCGN) has a current P/FCF of 0.00. The 5-year average P/FCF is -14.61. The thresholds are as follows: Strongly Undervalued below -82.50, Undervalued between -82.50 and -48.55, Fairly Valued between 19.33 and -48.55, Overvalued between 19.33 and 53.28, and Strongly Overvalued above 53.28. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Ocugen Inc (OCGN) has a current Price-to-Book (P/B) ratio of 95.75. Compared to its 3-year average P/B ratio of 8.44 , the current P/B ratio is approximately 1034.77% higher. Relative to its 5-year average P/B ratio of 11.85, the current P/B ratio is about 707.76% higher. Ocugen Inc (OCGN) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -31.15%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -23.17% , the current FCF yield is about -100.00% lower.

91.44

P/B

Median3y

8.44

Median5y

11.85

0.00

FCF Yield

Median3y

-31.15

Median5y

-23.17

Competitors Valuation Multiple

The average P/S ratio for OCGN's competitors is 70.43, providing a benchmark for relative valuation. Ocugen Inc Corp (OCGN) exhibits a P/S ratio of 398.24, which is 465.42% above the industry average. Given its robust revenue growth of 20.33%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Tonix Pharmaceuticals Holding Corp

Atea Pharmaceuticals Inc

Loss

298.67M

ESPR.O

Esperion Therapeutics Inc

Fennec Pharmaceuticals Inc

4.28

-65.52%

225.37M

Performance Decomposition

Market capitalization of OCGN decreased by 26.28% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 1.14M to 1.37M.

The secondary factor is the Margin Expansion, contributed -19.84%to the performance.

Overall, the performance of OCGN in the past 1 year is driven by Revenue Growth. Which is more sustainable.

20.33%

1.14M → 1.37M

Revenue Growth

-19.84%

-1.34K → -1.07K

Margin Expansion

-26.77%

-6.60 → -4.83

P/E Change

-26.28%